(NYSE: ZTS) Zoetis's forecast annual revenue growth rate of 4.8% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.72%.
Zoetis's revenue in 2025 is $9,286,000,000.On average, 7 Wall Street analysts forecast ZTS's revenue for 2025 to be $4,230,067,739,794, with the lowest ZTS revenue forecast at $4,196,976,315,631, and the highest ZTS revenue forecast at $4,258,882,495,401. On average, 7 Wall Street analysts forecast ZTS's revenue for 2026 to be $4,501,068,552,904, with the lowest ZTS revenue forecast at $4,439,169,496,463, and the highest ZTS revenue forecast at $4,542,057,077,511.
In 2027, ZTS is forecast to generate $4,755,925,231,595 in revenue, with the lowest revenue forecast at $4,643,702,528,092 and the highest revenue forecast at $4,893,616,952,187.